Skip to Main Content

Latest Advances

Which current drugs in the Dry Eye development pipeline have the greatest chance for success?

Is there a Mechanism of Action that stands out from the rest?
How do you see the OPI index being integrated into an FDA submission?
Have topical agents or systemic drugs been used to treat dry eye?
What do we know about the enervation of the meibomian gland? What regulates MG lipid secretion?
Is MGD part of the differential diagnosis of dry eye or at the core of dry eye?
What is the effect of dry eye chamber patient selection on labeling language for drug indications?
How do Dry Eye chamber results correlate from mice to humans?
What is the value of quality of life questionnaires in dry eye studies?
Is mean change from baseline in a sign or symptom an acceptable endpoint for primary approval?
What endpoints might be appropriate for studying a neurotrophy dry eye product candidate?
Is OPI a validated endpoint? How it might be used towards an FDA approval?
Lessons Learned in the Dry Eye Application Process - Panel Introduction
Images from the Inaugural Dry Eye Summit 2010

The 2010 Dry Eye Summit covered all aspects of dry eye drug development. The 2010 Dry Eye Summit was a unique one-day learning event that brought together the world’s thought leaders indry eye drug development. All will provide practical, usable advice on how to maximize your return on your dry eye drug development investment.
National Dry Eye Conference

Event Date:
Sat, 06/25/2011 - 9:00am - 4:00pm

Organizer:
Produced by the Sjögren's Syndrome Foundation Hosted by Ora Clinical Research

It is estimated that over 20 million people suffer from dry eye in the United States alone. If you are one of the many dealing with this debilitating chronic issue then you would benefit from our National Dry Eye Conference.
- Read more
- 1 attachment
Will there ever be a Dry Eye wonder drug?

Or is the better approach to Dry Eye drug development reliant upon the identification of unique sub-populations of Dry Eye sufferers?
How will devices play a part in the treatment of Dry Eye?

Right now, there are multiple devices in today’s pipeline. Is this just a blip in the dry eye development continuum, or are these devices here to stay?
Based on ingoing study design, what could the Dry Eye product label look like?
Does it make sense to invest in Dry Eye?
At which development stage do investors consider an investment in a Dry Eye product?
Keith Lane - Role of Blink - Dry Eye Summit

Share Your Content

Do you have or know about content you would like to see added to this website?

Submit your content

Categories

Dry Eye Summit Leaders

George . Ousler
Vice President, Dry Eye Ora, Inc.

Mark B. Abelson
Founder, Chairman, and CSO Ora, Inc.

Featured Galleries